LearnDrugs.com
Digestive / GI

Antiemetics

High-yield Verified · Jul 2026

Prototype: ondansetron

The 5-HT3 receptor antagonists (setrons, stem -setron) are the workhorse antiemetics. Other classes (D2, NK1, antihistamines) act at different sites — learn where each one works.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 What actually triggers vomiting — the serotonin signal

Vomiting is a reflex, coordinated by a "vomiting center" in the brainstem that receives inputs from several sources: a chemical-sensing area called the chemoreceptor trigger zone (CTZ / area postrema) that samples the blood, the gut via the vagus nerve, the inner ear (motion), and higher brain centers (sights, smells, anticipation). Different antiemetics work by silencing different inputs — which is why the right drug depends on *why* the patient is nauseated.

For the biggest triggers — chemotherapy, radiation, and surgery — the culprit signal is serotonin (5-HT). These insults damage the gut lining and make enterochromaffin cells in the gut dump serotonin, which fires 5-HT3 receptors on the vagal afferent nerves in the gut wall; that signal travels up the vagus to the brainstem and also acts on 5-HT3 receptors centrally in the CTZ. The setrons block those 5-HT3 receptors at both ends — peripherally in the gut (the predominant site) and centrally — cutting the emetic signal off at its source.

Chemo/radiation/surgery make the gut release serotonin, firing vagal 5-HT3 receptors — setrons block them.

02 One vomiting center, several drug classes — know the map

Because so many inputs feed the vomiting center, the antiemetics are best learned as a map of sites. The setrons (5-HT3) own chemo, radiation, and post-op nausea. Dopamine D2 antagonists — metoclopramide, prochlorperazine, promethazine — block the CTZ (metoclopramide also speeds gastric emptying). NK1 (substance-P) antagonists, the -pitants (aprepitant), are added to setrons for the most emetogenic chemo. Antihistamines and anticholinergics (meclizine, scopolamine) target the inner-ear/motion pathway — note the setrons are useless for motion sickness because that route isn’t serotonin-driven. Dexamethasone and cannabinoids round out chemo regimens.

A practical detail that follows from the pharmacology: setrons work best given prophylactically — before the emetogenic stimulus (before chemo, before the end of surgery) — because it is far easier to block the signal than to shut down vomiting already in full swing. Within the class, palonosetron is second-generation with a long half-life (~40 h), useful for *delayed* chemo nausea; and dolasetron’s IV form was pulled for chemo use over QT concerns, which is the perfect segue to the class’s signature risk.

Match the antiemetic to the trigger: serotonin (setrons) vs. dopamine, substance-P, or the vestibular route.

03 Why the QT warning follows — and the 32 mg story

The signature danger of the setrons is on the heart: they can prolong the QT interval, and ondansetron does this in a dose-dependent way. A longer QT means the ventricles take longer to reset electrically, which can degenerate into Torsades de Pointes, a life-threatening arrhythmia. The risk climbs with higher doses, with other QT-prolonging drugs, and with low potassium or magnesium — which is exactly why nurses correct electrolytes before dosing and are cautious in patients with congenital long-QT syndrome.

This isn’t theoretical. After a thorough-QT study, the FDA found that a single 32 mg IV dose of ondansetron prolonged the QT enough to be unsafe, and in 2012 that 32 mg IV dose was removed from the market — the maximum single IV dose is now 16 mg. (Oral dosing was not changed.) A second thing to know: setrons add to the body’s serotonin load, so combined with SSRIs, SNRIs, or MAOIs they carry a labeled risk of serotonin syndrome. Despite these real warnings, the setrons carry no boxed warning, and their formal contraindications are just two: apomorphine (profound hypotension) and hypersensitivity.

Ondansetron’s dose-dependent QT prolongation → the 2012 removal of the 32 mg IV dose; max single IV dose is now 16 mg.

Drug names

Generic Brand
ondansetron Zofran
granisetron Sancuso, Sustol
palonosetron Aloxi
dolasetron Anzemet

Indications

  • Chemotherapy-induced nausea & vomiting (CINV) — including delayed CINV (palonosetron)
  • Radiation-induced nausea & vomiting
  • Postoperative nausea & vomiting (PONV) — prophylaxis before end of surgery
  • Off-label: gastroenteritis, refractory nausea of pregnancy (specialist decision)

Mechanism of action

5-HT3 (serotonin-3) receptor antagonists competitively block 5-HT3 receptors at two sites: peripherally on vagal afferent nerve terminals in the GI tract (the predominant action) and centrally in the chemoreceptor trigger zone/area postrema. Chemotherapy, radiation, and surgery cause gut enterochromaffin cells to release serotonin, which would otherwise fire these receptors and trigger the emetic reflex; blocking them interrupts the signal at its source.

In plain terms
They block the serotonin "vomit" signal coming from the gut and brainstem, so the body doesn’t get the message to be sick.

Therapeutic effects — what you'll see working

Prevention beats rescue: given before chemo, radiation, or the end of surgery, setrons stop the emetic signal before it builds. Judge success by the absence or marked reduction of nausea and vomiting episodes.

Prevention of chemo/radiation nausea & vomiting Prevention of postoperative nausea & vomiting Control of delayed nausea (palonosetron)
Prevention of chemo/radiation nausea & vomiting
Blocking the 5-HT3 receptors that gut serotonin would fire prevents the acute wave of nausea and vomiting after emetogenic chemo or radiation — most effective when given before treatment. Success is simply the patient not vomiting.
Prevention of postoperative nausea & vomiting
A dose timed near the end of surgery blocks the emetic signal from anesthesia and the procedure, reducing PONV in the recovery period — a common, targeted use of a single IV dose.
Control of delayed nausea (palonosetron)
Palonosetron’s long half-life (~40 h) and high receptor affinity extend coverage into the delayed phase (days 2–5) of chemo nausea, where shorter-acting setrons fall short.

Adverse effects

Most setron patients get only a headache or constipation. The one thing not to miss is the cardiac risk — dose-dependent QT prolongation (ondansetron) worsened by low K⁺/Mg²⁺ and other QT drugs — plus additive serotonin syndrome. The setrons carry no boxed warning; the dopamine-antagonist antiemetic metoclopramide (mapped above) is the exception — it carries a tardive-dyskinesia boxed warning (below).

Caution: Common
Headache (most common), constipation, fatigue, dizziness; transient, asymptomatic elevation of liver enzymes (AST/ALT).
Headache is the single most frequent complaint, and constipation follows from slowed GI transit — assess bowel function and manage with fluids/fiber. The mild LFT bump is usually asymptomatic and self-limited.
Warning: Serious Hold & notify
Dose-dependent QT prolongation → Torsades de Pointes (ondansetron, dolasetron); serotonin syndrome with other serotonergic drugs; hypersensitivity/anaphylaxis (cross-reactive across setrons).
The headline risk is QT prolongation: it is dose-dependent, worse with other QT-prolonging drugs and with hypokalemia/hypomagnesemia, and can precipitate Torsades. Correct potassium and magnesium first, obtain a baseline ECG in at-risk patients, and do not exceed a 16 mg single IV dose of ondansetron. Combined with SSRIs/SNRIs/MAOIs, setrons can contribute to serotonin syndrome (agitation, tremor, hyperthermia, autonomic instability) — screen the med list and teach the warning signs.
Information: Regulatory note · no boxed warning (setrons)
Setrons carry no FDA boxed warning; the 32 mg single IV ondansetron dose was removed from the market in 2012 (max single IV dose now 16 mg).
The QT concern lives in the label’s Warnings and in FDA Drug Safety Communications, not a boxed warning. After a thorough-QT study, the FDA removed the 32 mg single IV dose in 2012; the maximum single IV dose is now 16 mg (oral dosing, including the 24 mg oral chemo dose, was unchanged).
Black-box warning — most severe: ■ Boxed warning · metoclopramide (D2 antagonist) Hold & notify
Metoclopramide can cause tardive dyskinesia — often irreversible. Avoid use beyond 12 weeks.
Unlike the setrons, the dopamine (D2) antagonist metoclopramide — used as an antiemetic and prokinetic — carries a boxed warning for tardive dyskinesia: involuntary, potentially irreversible movements of the face, tongue, and limbs. Risk rises with cumulative dose and duration, so treatment beyond 12 weeks should be avoided except in rare cases, and the drug stopped at the first sign of abnormal movements. Risk is higher in the elderly (especially women) and in diabetics.

Interactions

SSRIs, SNRIs, MAOIs (serotonergic drugs) drug
Additive serotonergic tone → risk of serotonin syndrome (agitation, tremor, hyperthermia, autonomic instability) — screen the med list.

Contraindications

Only two are formal contraindications (apomorphine, hypersensitivity); congenital long-QT is a strong "avoid" caution rather than an absolute bar, and the QT-drug/electrolyte cautions are what nursing acts on.

Concomitant apomorphine
The combination causes profound hypotension and loss of consciousness — a labeled contraindication with ondansetron.
Known hypersensitivity to the drug or another setron
Risk of anaphylaxis; hypersensitivity can be cross-reactive across the 5-HT3 antagonist class.
Congenital long-QT syndrome use caution
Additional QT prolongation risks Torsades — the label advises avoiding ondansetron; if unavoidable, monitor ECG closely.
Other QT-prolonging drugs, or uncorrected hypokalemia/hypomagnesemia use caution
These are additive with the setron’s own QT effect — correct electrolytes and reassess the drug list before dosing.
Give a setron safely — screen the heart and electrolytes, dose prophylactically, cap the IV dose.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Cardiac & electrolyte safety
Correct potassium and magnesium before dosing, and obtain a baseline ECG in patients with cardiac risk, other QT-prolonging drugs, or electrolyte disturbance.
Why: Hypokalemia and hypomagnesemia amplify the setron’s QT effect; correcting them and knowing the baseline QT reduce the risk of Torsades.
Do not exceed a 16 mg single IV dose of ondansetron; infuse IV doses over the recommended time rather than fast IV push.
Why: The 32 mg single IV dose was removed for unsafe QT prolongation; a slower infusion and a capped dose limit the peak effect on repolarization.
Administration & assessment
Give prophylactically — before chemo/radiation, or near the end of surgery for PONV — rather than waiting for vomiting to start.
Why: Blocking the emetic signal before it builds is far more effective than trying to abort established vomiting.
Screen for serotonergic drugs (SSRIs, SNRIs, MAOIs, tramadol, triptans) and monitor for serotonin syndrome.
Why: Setrons add to serotonergic tone; combined with these agents they can contribute to a potentially life-threatening reaction.
Assess bowel function and manage constipation with fluids and fiber; watch that antiemesis isn’t masking a worsening ileus or obstruction.
Why: Constipation is a common class effect, and controlling nausea can hide the pain/vomiting that would otherwise signal a mechanical GI problem.
Patient teaching
Report palpitations, fainting, or an irregular heartbeat, and the signs of serotonin syndrome (agitation, tremor, fever, sweating, confusion).
Why: These are the early warnings of the two serious risks — QT-related arrhythmia and serotonin syndrome — that need prompt attention.
Expect a possible headache and manage constipation; note orally disintegrating tablets contain phenylalanine (relevant in PKU).
Why: Knowing the common effects are expected keeps patients adherent, and the phenylalanine content matters for patients with phenylketonuria.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.